Baxter’s Gammagard Shows Alzheimer’s Benefit in Study

Baxter International Inc.’s Gammagard, used to treat immune system disorders, halted the progression of Alzheimer’s disease for as long as three years in a trial of 16 patients, researchers said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.